ReviewCells2024
Emerging Strategies in Mesenchymal Stem Cell-Based Cardiovascular Therapeutics.
Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Stem Cells and Their Derivatives in Cardiac Fibrosis Therapy: Challenges and Perspectives.Cells · 2026Review
- Pretreated mesenchymal stromal cells and their secretome for kidney disease: mechanisms and applications.Stem cell research & therapy · 2026Review
- HDAC6 inhibition reprograms endothelial and macrophage responses to protect the lung in endotoxemia.Respiratory research · 2026Article
- Umbilical Cord Mesenchymal Stem Cells as a Meritorious Option to Treat Psoriasis.Current stem cell research & therapy · 2026Review
- Cardiac Repair and Mesenchymal Stem Cells: Exploring New Frontiers in Regenerative Medicine.Current cardiology reviews · 2026Review
- Mesenchymal stem cells and their promise in reversing ovarian aging.Journal of ovarian research · 2025Review
- Smart Vesicle Therapeutics: Engineering Precision at the Nanoscale.Pharmaceutics · 2025Review
- Mesenchymal stem cell-derived microRNAs: Key immunomodulators to prevent ocular tissue degeneration.World journal of stem cells · 2025Review
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- Assessment of the Capability of Mesenchymal Stem Cells and/or Pyrroloquinoline Quinone in Compensating the Age-Related Dysfunctions of AMP-Activated Protein Kinase Pathway in Wistar Rats.Cell biochemistry and biophysics · 2025Article
- Use of regulatory cells for achieving functional tolerance of pig heart xenotransplants in humans: a literature review.Frontiers in immunology · 2025Review
- The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics.Frontiers in cell and developmental biology · 2025Review
- Umbilical cord mesenchymal stem cell exosomal miR-143-3p delays endothelial cell senescence through targeting COX-2.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cardiovascular diseases continue to challenge global health, demanding innovative therapeutic solutions. This review delves into the transformative role of mesenchymal stem cells (MSCs) in advancing cardiovascular therapeutics. Beginning with a historical perspective, we trace the development of stem cell research related to cardiovascular diseases, highlighting foundational therapeutic approaches and the evolution of cell-based treatments. Recognizing the inherent challenges of MSC-based cardiovascular therapeutics, which range from understanding the pro-reparative activity of MSCs to tailoring patient-specific treatments, we emphasize the need to refine the pro-regenerative capacity of these cells. Crucially, our focus then shifts to the strategies of the fourth generation of cell-based therapies: leveraging the secretomic prowess of MSCs, particularly the role of extracellular vesicles; integrating biocompatible scaffolds and artificial sheets to amplify MSCs' potential; adopting three-dimensional ex vivo propagation tailored to specific tissue niches; harnessing the promise of genetic modifications for targeted tissue repair; and institutionalizing good manufacturing practice protocols to ensure therapeutic safety and efficacy. We conclude with reflections on these advancements, envisaging a future landscape redefined by MSCs in cardiovascular regeneration. This review offers both a consolidation of our current understanding and a view toward imminent therapeutic horizons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.